Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) FCF Margin (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed FCF Margin for 8 consecutive years, with 1577.24% as the latest value for Q2 2025.

  • Quarterly FCF Margin changed N/A to 1577.24% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 4619.83% through Dec 2025, changed N/A year-over-year, with the annual reading at 667.83% for FY2025, N/A changed from the prior year.
  • FCF Margin for Q2 2025 was 1577.24% at Crescent Biopharma, up from 21695.8% in the prior quarter.
  • The five-year high for FCF Margin was 1577.24% in Q2 2025, with the low at 9589105.63% in Q2 2021.
  • Average FCF Margin over 3 years is 1617136.76%, with a median of 20639.14% recorded in 2021.
  • The sharpest move saw FCF Margin plummeted -6670709bps in 2021, then skyrocketed 956740984bps in 2022.
  • Over 3 years, FCF Margin stood at 72675.25% in 2021, then surged by 70bps to 21695.8% in 2022, then skyrocketed by 107bps to 1577.24% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 1577.24%, 21695.8%, and 72675.25% for Q2 2025, Q2 2022, and Q4 2021 respectively.